Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL

被引:0
作者
VHJ van der Velden
DCH Jacobs
AJM Wijkhuijs
WM Comans-Bitter
MJ Willemse
K Hählen
WA Kamps
ER van Wering
JJM van Dongen
机构
[1] Erasmus MC,Department of Immunology
[2] Erasmus University Medical Center,Department of Pediatrics
[3] Erasmus MC,Department of Pediatrics
[4] Erasmus University Medical Center,undefined
[5] Dutch Childhood Leukemia Study Group,undefined
[6] Beatrix Children's Hospital,undefined
来源
Leukemia | 2002年 / 16卷
关键词
minimal residual disease (MRD); peripheral blood; bone marrow; real-time quantitative PCR (RQ-PCR); immunophenotyping; childhood acute lymphoblastic leukemia (ALL);
D O I
暂无
中图分类号
学科分类号
摘要
Sensitive and quantitative detection of minimal residual disease (MRD) in bone marrow (BM) samples of children with acute lymphoblastic leukemia (ALL) is essential for evaluation of early treatment response. In this study, we evaluated whether the traumatic BM samplings can be replaced by peripheral blood (PB) samplings. MRD levels were analyzed in follow-up samples of 62 children with precursor-B-ALL (532 paired BM-PB samples) and 22 children with T-ALL (149 paired BM-PB samples) using real-time quantitative PCR (RQ-PCR) analysis of immunoglobulin and T cell receptor gene rearrangements with sensitivities of 10−3 to 10−5 (one ALL cell in 103 to 105 normal cells). In 14 of the 22 T-ALL patients, detectable MRD levels were found in 67 paired BM-PB samples: in 47 pairs MRD was detected both in BM and PB, whereas in the remaining pairs very low MRD levels were detected in BM (n = 11) or PB (n = 9) only. The MRD levels in the paired BM-PB samples were very comparable and strongly correlated (rs = 0.849). Comparable results were obtained earlier by immunophenotyping in 26 T-ALL patients (321 paired BM-PB samples), which also showed a strong correlation between MRD levels in paired BM and PB samples (rs = 0.822). In 39 of the 62 precursor-B-ALL patients, MRD was detected in 107 BM-PB pairs: in 48 pairs MRD was detected in both BM and PB, in 47 pairs MRD was solely detected in BM (at variable levels), and in 12 pairs only the PB sample was MRD-positive at very low levels (≤10−4). Furthermore, in the 48 double-positive pairs, MRD levels in BM and PB varied enormously with MRD levels in BM being up to 1000 times higher than in the corresponding PB samples. Consequently, BM samples cannot easily be replaced by PB sampling for MRD analysis in childhood precursor-B-ALL, in line with their BM origin. In T-ALL, which are of thymic origin, BM sampling might be replaced by PB sampling, because the dissemination of T-ALL cells to BM and PB appears to be comparable.
引用
收藏
页码:1432 / 1436
页数:4
相关论文
共 206 条
[1]  
Cave H(1998)Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group N Engl J Med 339 591-598
[2]  
van der Werff ten Bosch J(2000)Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia Blood 96 2691-2696
[3]  
Suciu S(1998)Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 352 1731-1738
[4]  
Guidal C(2000)Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia Blood 95 790-794
[5]  
Waterkeyn C(1998)Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia Blood 92 4072-4079
[6]  
Otten J(2001)Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia Leukemia 15 1485-1487
[7]  
Bakkus M(2001)Minimal residual disease in leukaemia patients Lancet Oncol 2 409-417
[8]  
Thielemans K(1997)Information booklet for parents of children surviving cancer Leukemia 11 1799-1806
[9]  
Grandchamp B(1992)Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction Leukemia 6 47-59
[10]  
Vilmer E(1999)Detection of minimal residual disease in acute leukemia by flow cytometry Cytometry 38 139-152